When B12 intake is already compromised by reduced food consumption on GLP-1, using the form that requires the fewest conversion steps makes sense
GLP-1 cardiovascular outcomes Multiple large-scale cardiovascular outcomes trials have demonstrated that GLP-1 agonists reduce the risk of major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death
The research was supported by the National Institutes of Health (grants R00AG049958, R01 DE027323, R56 DE025597, R01 DE026730, R01 DE021683, R21 DE024230, U01HL099776, U24DE026914, R21 DE019274, NIGMS K08GM109105, NIH R01GM123069 and NIH1R01AR071379), the California Institute for Regenerative Medicine, the Oak Foundation, the Pitch Johnson Fund, the Gunn/Olivier Research Fund, the Stinehart/Reed Foundation, The Siebel Foundation, the Howard Hughes Medical Institute, the German Research Foundation, the PSRF National Endowment, National Center for Research Resources, the Prostate Cancer Research Foundation, the American Federation of Aging Research and the Arthritis National Research Foundation.
What It Is AHK-Cu (alanine-histidine-lysine copper) is a tripeptide - three amino acids bound to a copper ion
Therefore formula is supplemented or the woman is discouraged entirely from breastfeeding
